TILT has multiple oncolytic immunotherapies for solid tumors in its pipeline.
A set of Phase I clinical trials of TILT-123 in various indications both as a monotherapy and in combination with immune checkpoint inhibitors or tumor-infiltrating lymphocyte (TIL) therapy have been completed with abount 100 patients treated across the studies. Patient enrollment for the Phase I trials listed below has now been completed.
For more information on contemplated future studies with the Phase II ready TILT-123.
TILT has a pipeline of early-stage assets & proprietary platform called TILT® technology.
- Product: TILT-321; TILT-322 Ad5/3 chimeric with bispecific antibody against Muc1
- Indication: Solid Tumors
- Description: T-cell recruitment into tumors and local activation. Local delivery of cytokine and/or bispecific antibody.
- Development status: Pre-clinical
- Product: TILT-234 Ad3
- Indication: Solid tumors
- Description: Enabling technology for Dendritic-cell therapy. Available for out-licensing.
- Development status: Pre-clinical
-
TILT-234 structure: Based on Adenovirus serotype 3 (Ad3) genome that is armed with human CD40L.
Our Technology
The power of TILT® technology enables TILT’s proprietary oncolytic viruses to be encoded with immunostimulatory cytokines and molecules, which have potential applicability across a wide range of solid tumor cancers.
Learn more about how the technology works: